VCM
CHRS icon

Versant Capital Management’s Coherus Oncology CHRS Stock Holding History

Versant Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-443
Closed -$1.66K – 1940
2023
Q3 		$1.66K Buy
+443
New +$2.05K ﹤0.01% 1365
2023
Q2 		– Sell
-767
Closed -$5.25K – 2053
2023
Q1 		$5.25K Buy
+767
New +$5.95K ﹤0.01% 921
2021
Q1 		– Sell
-52
Closed – – 1527
2020
Q4 		$0 Sell
52
-6
-10% -$107 ﹤0.01% 1357
2020
Q3 		$1K Buy
+58
New +$1.08K ﹤0.01% 1150

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Versant Capital Management's CHRS Position: Q4 2023 in Review

Versant Capital Management sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 443 shares — an estimated $1.66K sold.

Versant Capital Management first reported a position in CHRS in Q3 2020 and held it in 4 quarters. The position peaked at $5.25K in Q1 2023. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

  • Versant Capital Management reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
  • Versant Capital Management sold 443 Coherus Oncology shares in Q4 2023, an estimated $1.66K.
  • Versant Capital Management first reported a position in Coherus Oncology in Q3 2020 and held it in 4 quarters.
  • Versant Capital Management's Coherus Oncology position peaked at $5.25K in Q1 2023.
  • 156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Versant Capital Management's 13F filing for Q4 2023, filed 8 Jan 2024.